Clearmind Medicine

Clearmind Medicine is a biotechnology company developing psychedelic-derived treatments for neuropsychiatric, metabolic, and addiction disorders. Its research focuses on non-hallucinogenic neuroplastogens, with the aim of creating treatments that may be scalable and accessible beyond costly, supervised dosing models. The company’s first targeted indication is Alcohol Use Disorder, a condition for which Clearmind is pursuing new therapeutic approaches.

Clearmind’s proprietary lead investigational candidate, CMND-100, is based on MEAI, also known as 5-methoxy-2-aminoindane. The candidate is being evaluated in FDA-regulated Phase I/IIa clinical trials, hosted at Yale School of Medicine and Johns Hopkins University School of Medicine. These are investigational treatments and are not presented as approved medicines.

The company reports a portfolio of 19 utility patent families, including 32 granted patents, and is advancing additional treatment candidates and intellectual property. Clearmind also shares research, clinical-trial, and corporate updates for investors and other interested audiences. With offices in Vancouver and Tel Aviv, the company works at the intersection of medicine, biotechnology, and drug development.